PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
P-C10 SAFETY ASSESSMENT OF NANOMEDICINES/NANODEVICES: CURRENT GUIDELINES ARE SUFFICIENT TO ENSURE SAFETYJoan-Albert Vericat, Isolde Anglade, Nicolas Fabre Neuropharma SA, Madrid (Spain)